AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ACRV

Miller Mary sold $944 of ACRV

Miller Mary (Chief Legal Officer) sold 513 shares of Acrivon Therapeutics, Inc. (ACRV) at $1.84 on 2026-10-22.

Original reporting
SEC EDGAR · Miller Mary
Published Oct 26, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACRV
Neutral
high confidence
Mentioned
$ACRV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACRVNeutralLow
01

Why it matters

The filing provides the first public disclosure of this insider transaction, offering a data point for traders monitoring insider activity.

02

Market read

A small insider sell with limited immediate market impact, but useful for monitoring insider sentiment.

03

What to watch

No accompanying news on product or financial performance to contextualize the sale.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing by Acrivon Therapeutics' Chief Legal Officer reporting an open‑market sale of shares.

Company-level read

Ticker impact

$ACRVNeutralHigh confidence
Context

Chief Legal Officer sold 513 shares for $943.92 in a Form 4 filing, indicating insider selling pressure.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

Form 4 disclosures are primary source; the sale size is small but signals possible insider sentiment.

Market effects

Sector

Minimal impact on the biotech sector; isolated insider transaction.

Regional

Negligible effect on broader market.

Global

Limited to ACRV shareholders.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing and not indicative of company fundamentals.

Key entities

  • Officer
    Miller Mary

    Chief Legal Officer of Acrivon Therapeutics, reporting the sale.

  • Company
    Acrivon Therapeutics, Inc.

    Biotech firm listed on US exchanges under ticker ACRV.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACRV insider trading history →

Related articles

$ACRVMedAI 8/10

Acrivon to present cancer drug trial data at November symposium

Acrivon Therapeutics (ACRV) will present Phase 1/2 trial data for ACR-2316 at a cancer symposium in November. The study showed clinical activity in endometrial and lung cancers, with one patient achieving complete response. The trial has progressed to dose expansion, including pancreatic cancer patients. ACRV uses its AP3 platform to predict patient responses.

investing.com
$ACRVMedAI 8/10

Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing

Acrivon Therapeutics (ACRV) announced the advancement of ACR-7280, an oral CDK11 inhibitor, as its next development candidate. The company plans to file an IND application for the drug with the FDA in the first half of 2027. ACR-7280 showed complete tumor regression in AML xenograft models and potential in combination therapies. Acrivon's lead program, ACR-368, is in a Phase 2 trial for endometrial cancer.

investing.com
$ACRVMed

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 P

SEC EDGAR 8-K